Rapid Study Start-up for Phase 1 Dermatology Study in Australia for a UK Biotech Company

How PharmaSols Supported Phase 1 Dermatology Study in Australia





PharmaSols was contracted by a small UK-based biotech company to conduct a Phase 1 dermatology clinical trial in Australia. The sponsor was looking to get the study started within a short period of time to achieve the ‘first patient in’ milestone for their investors.  

Australia has some of the fastest and most streamlined ethics and regulatory frameworks, enabling the first patient to be enrolled faster than anywhere else in the world. Due to this, the sponsor selected Australia as the destination of their clinical trial. 

Choosing a CRO who knows and understands the nuances of the region in which the trial is being conducted is highly beneficial. Despite Australia’s relatively straightforward regulatory processes, there are unique regional and cultural requirements that play vital roles in the application process. 

PharmaSols was considered a good fit for the small biotech as a knowledgeable and well-connected CRO in Australia – with strong, longstanding relationships with ethics and regulatory body representatives and established relationships with trial sites and local experts. This can have a significant impact on the success of a clinical trial.  

The sponsor also recognised the importance of PharmaSols’s specialised regional expertise in navigating the complex ethics and regulatory environments, as well as its reputation as a CRO that delivers efficient and flexible solutions within tight timeframes and limited budgets.  


Our key strategies to achieve a 3-month start-up


PharmaSols employed a proactive approach to achieve rapid start-up, focusing on swift ethics and regulatory approvals and concurrent site activation. 

PharmaSols has a dedicated rapid start-up team consisting of regulatory and clinical professionals with more than 20 years of experience in the ANZ clinical trial industry. 

This team understands country-specific and regional regulations, enabling us to implement proactive solutions to potential challenges and accelerate the timelines from trial site selection to first patient in. 

We were able to achieve the start-up for this Phase 1 dermatology study in a rapid 3-month window. 

The full regulatory approval was achieved merely 40 days from the final protocol receipt. The team worked tirelessly to ensure the first SIV was achieved only 4 days after the full regulatory and ethics approvals were granted. The first patient was screened only 3 days after site activation. 


Our team implemented four key strategies: 

  • Streamlined communication: Ensuring immediate internal kickoff post-final protocol receipt to align all stakeholders. 
  • Efficient submission process: Preparing the pre-ethics submission and submited key documents just 10 days after receiving the final protocol to meet the prescribed ethics meeting dates by the committee. 
  • Rapid response to challenges: Addressing the requirement for an ethics re-submission with additional information promptly to mitigate potential delays. 


Successful Outcomes and Study Continuation 


At PharmaSols, our Start-Up team strategically leverages our position in Australia. Our proven track record underscores the effectiveness of our approach, emphasising that clinical trials can be swift, efficient, and cost-effective whilst maintaining the highest standards of excellence. 

Our team delivered a well-coordinated, collaborative and customised approach to support this small biotech achieve their rapid start-up timeline of just 3 months.  

Our deep and comprehensive service allowed us to guide our overseas client team effectively. We provided crucial regional support, flexibility, and tailored solutions to ensure that all regulatory and safety/quality aspects were considered and study milestones were achieved. Our strong partnership with the client assured rapid attention and proactive solutions to any potential issues. 

As the study progresses, continuous monitoring and adaptive management strategies will be essential to maintain momentum and promptly address any challenges.  

Recruitment efforts remain underway, so stay tuned for updates on patient recruitment for this Phase 1 dermatology study. 

Case Studies

Successful Phase 2 Obesity Clinical Trial in the ANZ Region for a US Biotech Company

PharmaSols was contracted by a small US-based biotech company to conduct a Phase 2 obesity clinical trial. The study required the recruitment of 325 eligible participants across 16 sites in Australia and New Zealand.

Read more
PharmaSols achieve rapid start-up for complex 1b oncology study

A US-based biopharmaceutical company was looking to run a Complex 1b Oncology study. The study needed to be handled by a CRO that could manage tight timeframes, and it was imperative that it be carried out without costly interruptions.

Read more
Creating Solutions to Deliver Rapid & High-Quality Clinical Trials

Our team have needed to respond quickly to challenges supporting different studies and the experience of our team has enabled us to create rapid solutions for our global sponsors.

Read more
Expedited Timeframes and Exceeded Targets for COVID-19 Diagnostic Trial

PharmaSols were engaged by an organisation looking to run a clinical trial for a COVID-19 diagnostic test. It was imperative that this study be carried out without costly interruptions and needed to be handled by a CRO that could manage tight timeframes.

Read more
Patient Recruitment Targets Exceeded for COVID-19 Vaccine Trial

Due to PharmaSols unique location and history of successful rapid start-ups, we were engaged by a European specialty vaccine company running a COVID-19 vaccine study. This study needed to be conducted without interruptions caused by the virus itself and with a CRO that could handle tight recruitment timeframes.

Read more
Expedited Timelines and Recruitment Success for COVID-19 Vaccine Trial

While the pandemic has slowed down most of the globe, it has increased the demand for rapid solutions within the pharmaceutical industry, with an urgent need to find a vaccine and COVID-19 related treatments and vaccines. Running clinical trials for potential solutions is a vital element in this process.

Read more
Exceeding Site Identification Targets Across Three Recent Clinical Trial Studies

Site identification is the first and most critical deliverable from a CRO. Without an appropriate site, there is no patient recruitment, and without patients, there is no study.

Read more
High Recruitment: Twice as many patients as global CRO

Faced with a challenging recruitment process, needing to recruit a large number of elderly participants within a tight three-month seasonal recruitment window, a US-based Biotech Company appointed PharmaSols as the NZ CRO for this phase three respiratory clinical trial.

Read more
Rapid start-up: First SIV in less than 35 days

Having previously worked with PharmaSols over a number of trials, the US sponsor knew that the PharmaSols team could deliver on both tight start-up timelines and high recruitment targets. PharmaSols proven record of flexible, rapid, and creative solutions meant we were the ideal CRO partner.

Read more
Creative Solutions for US Biotech Clinical Trial

A US-based Biotech company was seeking a CRO who could successfully recruit a large number of elderly research participants in New Zealand. A challenge that was not only squeezed into a three-month seasonal recruitment window but was also met with issues so unique, there were no established protocols.

Read more
Rapid Start-up and Tight FPI Timeline for US Biotech Clinical Trial

After a sudden decision to expedite their study timelines, a US Biotech company approached PharmaSols in need of a CRO who could successfully achieve a quality rapid start-up within a tight timeline.

Read more
Quick Feasibility for Rare Genetic Trial

A US Biotech company reached out to PharmaSols, to investigate the feasibility of running a trial in New Zealand on participants' stored tissue samples, where consent had been given for further research to identify a rare genetic marker.

Read more